FDA Determines Regulatory Review Period for PEG-Intron Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for PEG-Intron, a human biological product, in response to a patent extension application submitted to the US Department of Commerce.